Literature DB >> 26788221

Painful neuropathy in a diabetic patient resulting from lung cancer and not diabetes: A case report.

He-Bin Yao1, Ya-Ning Chen1, Jian Shang1, Qiao-Jun Han1.   

Abstract

The current study reports the case of a 61-year-old man with diabetes who was suffering from generalized pain over the whole body and gradually progressive numbness. The patient was initially diagnosed with diabetic peripheral neuropathy and received treatment, however, the symptoms persisted. In October 2010, the patient was admitted to the Chinese People's Liberation Army Navy General Hospital (Beijing, China) for the treatment of diabetes, however, a full-body sharp pain was also described, which was relieved upon massaging the area. Causes, other than diabetes, were investigated for these symptoms. Chest computed tomography and positron emission tomography-computed tomography scans revealed a mass shadow in the right lower lobe of the lung, with multiple lymphatic metastases. Lung cancer was diagnosed with a tumor-node-metastasis stage of T1N3Mx. Following treatment of the cancer with chemotherapy and radiotherapy, the patient's symptoms were significantly improved. The present study reports a rare case of a paraneoplastic neurological syndrome (PNS) that presented as painful neuropathy resulting from lung cancer, which mimicked diabetic peripheral neuropathy.

Entities:  

Keywords:  diabetic peripheral neuropathy; lung cancer; paraneoplastic neurological syndrome

Year:  2015        PMID: 26788221      PMCID: PMC4665967          DOI: 10.3892/ol.2015.3808

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  15 in total

1.  [Diabetic neuropathies].

Authors:  J P Azulay; J Pouget
Journal:  Rev Prat       Date:  2001-10-15

Review 2.  The Semmes Weinstein monofilament examination as a screening tool for diabetic peripheral neuropathy.

Authors:  Yuzhe Feng; Felix J Schlösser; Bauer E Sumpio
Journal:  J Vasc Surg       Date:  2009-07-30       Impact factor: 4.268

3.  Global estimates of diabetes prevalence for 2013 and projections for 2035.

Authors:  L Guariguata; D R Whiting; I Hambleton; J Beagley; U Linnenkamp; J E Shaw
Journal:  Diabetes Res Clin Pract       Date:  2013-12-01       Impact factor: 5.602

Review 4.  Activated microglia in the spinal cord underlies diabetic neuropathic pain.

Authors:  Dongmei Wang; Réjean Couture; Yanguo Hong
Journal:  Eur J Pharmacol       Date:  2014-02-06       Impact factor: 4.432

Review 5.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 6.  Screening for peripheral neuropathies in children with diabetes: a systematic review.

Authors:  Gerrit Hirschfeld; Michael von Glischinski; Markus Blankenburg; Boris Zernikow
Journal:  Pediatrics       Date:  2014-04-07       Impact factor: 7.124

Review 7.  Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

8.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

9.  Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China.

Authors:  Pian-Hong Zhang; Zhong-Wen Chen; Duo Lv; Yu-Yang Xu; Wei-Ling Gu; Xu-Hui Zhang; Yuan-Luo Le; Hong-hong Zhu; Yi-Min Zhu
Journal:  BMC Public Health       Date:  2012-07-28       Impact factor: 3.295

10.  Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin.

Authors:  Aaron I Vinik; Carolina M Casellini
Journal:  Diabetes Metab Syndr Obes       Date:  2013-02-22       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.